Exact Sciences Stockholders Approve Abbott Acquisition with Over 80% Vote
Exact Sciences stockholders approved Abbott’s proposed acquisition, securing the required two-thirds vote with over 80% support. The all-stock transaction is slated to close in Q2 2026 after customary regulatory clearances, integrating Exact Sciences’ early cancer detection tests into Abbott’s diagnostics portfolio.
1. Stockholder Vote Approval
Exact Sciences stockholders cast more than 80% of votes in favor, meeting the required two-thirds shareholder approval threshold and greenlighting Abbott’s proposed acquisition.
2. Transaction Overview
Under the all-stock terms, Exact Sciences holders will receive Abbott shares, positioning the combined entity to leverage Exact’s cancer screening and molecular diagnostic tests across Abbott’s global diagnostics network.
3. Timeline and Regulatory Approvals
The acquisition is expected to close in Q2 2026, subject to antitrust and other customary regulatory approvals, after which integration planning and operational alignment will commence.